Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx Corporation (Nasdaq: LUNG) recently closed its initial public offering, selling 11,500,000 shares of common stock at $19.00 per share. This includes the full exercise of underwriters' options for 1,500,000 additional shares. The gross proceeds from the offering reached approximately $218.5 million, prior to deductions for underwriting discounts and commissions. Shares began trading on The Nasdaq Global Select Market on October 1, 2020. BofA Securities and Morgan Stanley served as joint lead managers for the offering.
Pulmonx Corporation has announced the pricing of its upsized initial public offering (IPO) of 10,000,000 shares at $19.00 each, totaling gross proceeds of $190 million. The offering includes a 30-day option for underwriters to purchase an additional 1,500,000 shares. Trading on the Nasdaq under the symbol 'LUNG' will commence on October 1, 2020, with the expected close on October 5, 2020. BofA Securities and Morgan Stanley lead the offering, which was declared effective by the SEC on the same day.